NASDAQ · BIOX
Bioceres Crop Solutions financials
$0.3455−3.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Jun 30 | FY24 Jun 30 | FY23 Jun 30 | FY22 Jun 30 | FY21 Jun 30 | FY20 Jun 30 | FY19 Jun 30 |
|---|---|---|---|---|---|---|---|
| Revenue | $333.3M | $464.8M | $419.4M | $328.5M | $209.5M | $173.1M | $160.6M |
| Gross profit | $129.9M | $186.6M | $184.0M | $120.1M | $90.9M | $79.5M | $73.6M |
| Gross margin | 39.0% | 40.1% | 43.9% | 36.6% | 43.4% | 45.9% | 45.9% |
| Operating income | -$2.9M | $41.8M | $52.4M | $32.3M | $37.4M | $36.7M | $31.1M |
| Net income | -$55.4M | $4.3M | $18.8M | -$7.2M | -$6.9M | $3.4M | -$18.4M |
| Net margin | −16.6% | 0.9% | 4.5% | −2.2% | −3.3% | 1.9% | −11.4% |
| Diluted EPS | $-0.88 | $0.07 | $0.30 | $-0.17 | $-0.18 | $0.09 | $-0.60 |
| EBITDA | $14.3M | $59.7M | $68.2M | $40.3M | $42.8M | $40.8M | $35.9M |
| Operating cash flow | $49.9M | $41.7M | $2.6M | -$17.5M | -$6.2M | $9.3M | $29.7M |
| Free cash flow | $44.3M | $31.9M | -$8.8M | -$26.1M | -$12.9M | $6.4M | $27.0M |
| Diluted shares | 63.2M | 63.5M | 63.2M | 42.3M | 39.2M | 36.4M | 30.5M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $32.7M | $44.5M | $48.1M | $33.5M | $36.0M | $42.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $308.7M | $259.7M | $243.5M | $158.0M | $173.4M | $148.0M |
| Total assets | $763.6M | $852.5M | $818.1M | $518.2M | $394.6M | $297.6M |
| Total liabilities | $468.4M | $501.2M | $487.6M | $359.9M | $304.3M | $236.8M |
| Shareholders' equity | $295.2M | $351.4M | $330.5M | $158.3M | $90.3M | $60.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology